Minocycline protects against neuronal mitochondrial dysfunction and cognition impairment

dc.contributor.authorMotaghinejad, Majid
dc.contributor.authorMotevalian, Manijeh
dc.contributor.authorUlloa, Luis
dc.contributor.authorKaviani, Neda
dc.contributor.authorHamurtekin, Emre
dc.date.accessioned2026-02-06T18:21:56Z
dc.date.issued2023
dc.departmentDoğu Akdeniz Üniversitesi
dc.description.abstractThe potential of minocycline to protect against methylphenidate-induced neurodegeneration has been extensively reported in the literature but the mechanism of action is still unknown. This study aims to determine the role of mitochondrial chain enzymes and redox homeostasis on the neuroprotective effects of minocycline in methylphenidate-induced neurodegeneration. Wistar adult male rats were randomly assigned to the seven experimental groups: Group 1 received saline solution; Group 2 received methylphenidate (10 mg/kg, i.p.); Groups 3, 4, 5, and 6 received methylphenidate and minocycline for 21 days; Group 7 received minocycline alone. Cognition was evaluated with the Morris water maze test. Activity of the hippocampal mitochondrial quadruple complexes I, II, III and IV, mitochondrial membrane potential, adenosine triphosphate (ATP) levels, total antioxidant capacity, and reactive oxygen species were determined. Treatment with minocycline inhibited methylphenidate-induced cognitive dysfunction. Minocycline treatment increased mitochondrial quadruple complex activities, mitochondrial membrane potential, total antioxidant capacity, and ATP levels in the dentate gyrus and cornu ammonis-1 (CA1) areas of the hippocampus. Minocycline is likely to confer neuroprotection against methylphenidate-induced neurodegeneration and cognition impairment by regulating mitochondrial activity and oxidative stress.
dc.description.sponsorshipResearch Deputy of Iran University of Medical Sciences [16837]
dc.description.sponsorshipThis project was supported financially by the Research Deputy of Iran University of Medical Sciences (Project Number. 16837).
dc.identifier.doi10.55782/ane-2023-008
dc.identifier.endpage83
dc.identifier.issn0065-1400
dc.identifier.issn1689-0035
dc.identifier.issue1
dc.identifier.orcid0000-0002-7702-7549
dc.identifier.pmid37078816
dc.identifier.scopus2-s2.0-85153413380
dc.identifier.scopusqualityQ4
dc.identifier.startpage71
dc.identifier.urihttps://doi.org/10.55782/ane-2023-008
dc.identifier.urihttps://hdl.handle.net/11129/9551
dc.identifier.volume83
dc.identifier.wosWOS:001159271800009
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherNencki Inst Experimental Biology
dc.relation.ispartofActa Neurobiologiae Experimentalis
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260204
dc.subjectmethylphenidate
dc.subjectminocycline
dc.subjectmitochondria
dc.subjectcognition
dc.titleMinocycline protects against neuronal mitochondrial dysfunction and cognition impairment
dc.typeArticle

Files